





LITHUANIA

Recent and planned developments in pharmaceutical policies 2017

Special topic: hospital medicines

CHANGES IN PRICING	CHANGES IN REIMBURSEMENT
Image: The following measures are implemented in pricing of reimbursed medicinal products: • If the INN is produced by 3 and more producers the declare price of medicinal products could not exceed the average of reference price of the cheapest products more than 10% (objective – decrease of patient copayment) Image: Image	In 2017 start reimbursed 14 new active substance: (medicinal products used in the in vitro fertilization (IVF) procedure, direct factor Xa inhibitors, direct thrombin inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitors and etc.)
OTHERS CHANGES	
 Start HTA pilot project; Guidelines of pharmaceutical policy (rational use of medicines, pricing of medicines, use of generics, real data collection an etc.) SPECIAL TOPIC: HOSPITAL MEDICINES	
IN-PATIENT REIMBURSEMED MEDICINES	
Centrally Procured medicines	Hospital medicines
In-patient pharm. expenditureImage: Procurements2016: 46 Mio. Euro (estimation, 7,2 % of TPE)-done by NHIF -expensive medicines used in hospital facilities, which are needed by 500 or less patients per year	In-patient pharm. expenditureProcurements2016: 89 Mio. Euro (estimation, 12,7% of TPE)-by Central procuring organization (CPO) or hospitals -tendering procedure -no joint procurement -medicines are free of charge for patient and the cost of medicines is included in the price of the medical service -negotiations with pharmacy company - actual purchasing prices are not published